According to Piper Jaffray, Alnylam Pharmaceuticals ALNY, EPS estimates have been revised.
Piper Jaffray announced a decrease in FY11 EPS estimates from ($1.31) to ($1.33) and an increase in FY12 EPS estimates from ($1.86) to ($1.82). Rating of neutral and PT of $10 are both reiterated.
Alnylam closed yesterday at $9.40.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in